A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re
A phase 3 trial of Mezigdomide, Pomalidomide, Bortezomib in multiple myeloma, run by Celgene, now recruiting.
Overview
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) is a phase 3 interventional study registered as NCT05519085 by Celgene, with 810 participants planned, started 2022-09-20 and due to reach its primary completion in 2027-01-10. Interventions recorded: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialA Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre
Shares Mezigdomide, Bortezomib, Dexamethasone, Bristol Myers Squibb.
- TrialA Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed
Shares Mezigdomide, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.
- TrialAll Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants
Shares Bortezomib, Dexamethasone, Bristol Myers Squibb, Multiple myeloma.